The Philippines national Department of Science and Technology reports that 21 subjects have been enrolled in a clinical trial for an adjunctive therapy targeting COVID-19 involving a medicinal plant known as Lagundi. The trial sites include Quezon Institute Quarantine Center, Sta Ana Hospital and PNP-NCRPO Bagong Diwa Quarantine Center. With 113 patients screened, the study was actually approved by the Philippines Food and Drug Administration (FDA) in August. The ethics of this study was cleared by the University of the Philippines (UP)—Manila Research Ethics Board.
What is Lagundi?
Commonly known as “Chaste tree,” “five-leaved chaste tree,” or “horseshoe vitex” or “nishinda,” this large aromatic shrub is used as a traditional folk medicine in South and Southeast Asia. The Food and Drug Administration of the Philippines has approved for use in COVID-19 clinical trials. TrialSite reported in July that the Philippines Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD) approved the clinical trial investigating the use of an herbal medicine called “Lagundi” as a therapeutic supplement for COVID-19. The study was also cleared by the University of the Philippines (UP) Manila Research Ethics Board, reports DOST Secretary Fortunato de la Peña. Interestingly, this government research agency issued a press release prior to securing that nation’s FDA approval.
TrialSite News works with collaborative correspondents around the world to track relevant and important clinical trials. This will include correspondent updates in Southeast Asian nations, such as the Philippines. With nearly 110 million people, the Philippines represents the world’s 12th most populated nation and an important place; and although economically still well in the “developing nations” category, the country represents a tactical hub for health and life science firms seeking expansion.
Call to Action: TrialSite readers request the tracking of some of these Asian and other tropical medicinal plants also known as “folk” or “traditional” medicine. TrialSite accommodates as long as the clinical trial is approved by the relevant authorities in the specific nation.